Mar 05, 2024 / 05:50PM GMT
Tyler Martin Van Buren - TD Cowen, Research Division - MD & Senior Equity Research Analyst
Welcome and good afternoon everyone. Welcome again to TD Cowen's 44th Annual Healthcare Conference, Day 2. My name is Tyler Van Buren, Senior Biotech Analyst here. For our next session, very pleased to have a fireside chat with Gilead. And from Gilead, it's my pleasure to introduce Andy Dickinson, Chief Financial Officer. Andy, thank you very much for being here.
Andrew D. Dickinson - Gilead Sciences, Inc. - Executive VP & CFO
Thank you, for us all to be here again. Thanks for having us.
Tyler Martin Van Buren - TD Cowen, Research Division - MD & Senior Equity Research Analyst
So before I get started, if you guys have questions, chime in or raise your hand and we'll do our best to get them asked. So to open, Andy, I wanted to start with Gilead's 2024 guidance and a high-level overview of the business. And perhaps you could elaborate on some of the assumptions behind the 5% year-over-year product sales growth,
Gilead Sciences Inc at TD Cowen Health Care Conference Transcript
Mar 05, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers